The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Wendy R. Parulekar
No Relationships to Disclose
 
Urban Emmenegger
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Knight Therapeutics; Merck
Research Funding - Astellas Pharma; Bayer; Janssen
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SignalChem (Inst)
Travel, Accommodations, Expenses - Eisai
 
Frederic Pouliot
No Relationships to Disclose
 
Glenn Bauman
Honoraria - Bayer
Research Funding - Siemens (Inst)
(OPTIONAL) Uncompensated Relationships - Centre for Probe Development and Commercialization
 
Katherine A. Zukotynski
No Relationships to Disclose
 
Stuart Peacock
No Relationships to Disclose
 
Alexander William Wyatt
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca Canada; Janssen; Merck
Consulting or Advisory Role - AstraZeneca
Research Funding - ESSA (Inst)
 
Jean-Mathieu Beauregard
Honoraria - Ipsen; Novartis
Research Funding - Ipsen (Inst); Novartis (Inst); Point Biopharma (Inst)
 
Justin Lee
Honoraria - TerSera
 
Carlos Uribe
No Relationships to Disclose
 
Conor Dellar
No Relationships to Disclose
 
Keyue Ding
No Relationships to Disclose
 
Francois Benard
No Relationships to Disclose